Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with a specific type of prostate cancer (prostatic adenocarcinoma, not the small cell type), confirmed through a tissue or cell sample
• People whose cancer has spread to other parts of the body, as shown on imaging scans
• People whose cancer has continued to grow or spread after previous treatment with a therapy called 177Lu-PSMA-617, as determined by the trial doctor
• People who are well enough to carry out basic daily activities, based on a standard health performance scale (score of 2 or lower)
• People whose blood counts, liver, kidney, and other organ function results fall within the ranges required by the trial
• People who are willing to use highly effective contraception during the trial and for 96 days after the last dose, plus an additional barrier method such as a condom, and who agree not to donate sperm during this time
• People who have recovered from side effects of any previous cancer treatment to an acceptable level as determined by the trial doctor
• People who are able to understand the study and are willing to sign a consent form

Who may not be able to join:

• People who have previously been treated with a drug called XL092
• People who have received certain anticancer medicines, including targeted therapy pills, chemotherapy, biological therapies, or other systemic cancer treatments within 2 weeks (or within 5 half-lives of the drug, whichever is shorter) before starting the trial
• People who have had radiation therapy to the bones or any other area within 2 weeks before starting the trial, or who are still experiencing significant complications from previous radiation treatment
• People with cancer that has spread to the brain or surrounding tissue, unless it has been treated and has been stable for at least 4 weeks before starting the trial, and the person has no neurological symptoms and is not taking steroid medications at that time (confirm with trial site for specific exceptions)
• People taking certain blood-thinning medications by mouth, with some exceptions for low-dose or specific types approved under the trial's guidelines (confirm with trial site)
• People who have used herbal supplements or traditional medicines to treat their cancer within 2 weeks (or within 5 half-lives, whichever is shorter) before starting the trial
• People with serious or uncontrolled heart conditions, such as severe heart failure, unstable chest pain, or dangerous heart rhythm problems
• People with uncontrolled high blood pressure that remains above set limits despite medication
• People who have had a stroke, mini-stroke (TIA), heart attack, or other significant blockage-related event within 6 months before starting the trial
• People who have had a blood clot in the lungs or a deep vein clot within 3 months before starting the trial (confirm with trial site for specific exceptions)
• People with serious stomach or bowel conditions, including active ulcers, inflammatory bowel disease, recent bowel blockage, recent perforation or fistula, known varices in the stomach or oesophagus, or certain other gastrointestinal complications (confirm with trial site for full list)
• People who have had clinically significant bleeding, such as coughing or vomiting more than half a teaspoon of blood, within 12 weeks before starting the trial
• People with certain lung conditions, such as cavities in the lungs or tumours affecting the airways
• People with tumours growing into or invading major blood vessels
• People with an active infection currently being treated with antibiotics or other systemic medicines
• People with known hepatitis B, hepatitis C, HIV, or AIDS
• People who have had a confirmed or suspected COVID-19 (SARS-CoV-2) infection within one month before joining (unless the trial doctor confirms full recovery)
• People with serious wounds, ulcers, or bone fractures that have not healed
• People with a condition that affects absorption of medicines taken by mouth
• People with uncontrolled underactive thyroid causing symptoms
• People with moderate to severe liver disease (Child-Pugh B or C)
• People who require dialysis (kidney replacement therapy)
• People who have had a solid organ transplant or stem cell transplant from a donor
• People who have had major surgery within 8 weeks before starting the trial, certain keyhole surgery within 4 weeks, or minor surgery within 10 days, or whose surgical wounds have not fully healed
• People with a specific abnormal heart rhythm measurement (QTcF greater than 480 ms on an ECG) within 14 days before starting the trial
• People with a history of a psychiatric condition that could affect their ability to follow the study requirements or provide informed consent
• People who are unable to swallow tablets
• People with a known allergy or sensitivity to any ingredient in the study treatment
• People who have had another active cancer diagnosis, or been treated for another cancer with systemic therapy, within 2 years before starting the trial (with some exceptions for certain low-risk skin cancers or cured localised tumours, as determined by the trial doctor)
• People taking certain prohibited medications unless an appropriate washout period has been completed
• People who, in the trial doctor's opinion, have other conditions that would make participation unsafe or difficult to complete

Important: Always verify eligibility with the trial site directly before applying.